vidarabine phosphate and Leukocytopenia

vidarabine phosphate has been researched along with Leukocytopenia in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (28.57)	18.7374
1990's	4 (57.14)	18.2507
2000's	1 (14.29)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abali, H; Aksoy, S; Dinçer, M; Erman, M; Kilickap, S	1
Abassi, ZA; Carter, A; Green, J; Nakhoul, F	1
Athan, E; Fein, S; Fiedor, PS; Goodman, ER; Hardy, MA	1
Cassileth, P; Hochster, H	1
Alberts, DS; Green, S; Hannigan, EV; Surwit, EA; Von Hoff, DD	1
Casper, ES; Kelson, D; Mittelman, A; Young, CW	1
Baker, LH; Pazdur, R; Samson, MK	1

Reviews

1 review(s) available for vidarabine phosphate and Leukocytopenia

Article	Year
Tumor lysis syndrome induced by fludarabine monophosphate: a case report. European journal of haematology, 1996, Volume: 56, Issue:4 Topics: Acute Kidney Injury; Allopurinol; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Middle Aged; Sodium Bicarbonate; Tumor Lysis Syndrome; Vidarabine Phosphate	1996

Trials

1 trial(s) available for vidarabine phosphate and Leukocytopenia

Article	Year
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. American journal of clinical oncology, 1990, Volume: 13, Issue:5 Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; United States; Uterine Cervical Neoplasms; Vidarabine Phosphate	1990

Other Studies

5 other study(ies) available for vidarabine phosphate and Leukocytopenia

Article	Year
Fludarabine phosphate may be useful in the treatment of graft-versus-host disease. Medical hypotheses, 2005, Volume: 64, Issue:6 Topics: Animals; Antimetabolites; Antineoplastic Agents; CD4 Lymphocyte Count; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukocyte Reduction Procedures; Leukopenia; Mice; Stem Cell Transplantation; T-Lymphocyte Subsets; Vidarabine Phosphate	2005
Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. The American surgeon, 1996, Volume: 62, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; B-Lymphocytes; Bone Marrow; Bone Marrow Cells; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; DNA; Endonucleases; Graft Survival; Humans; Immunization; Immunosuppressive Agents; Leukocytes, Mononuclear; Leukopenia; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Depletion; Macaca fascicularis; Mitogens; Neutropenia; Papio; Phytohemagglutinins; Skin Transplantation; Swine; T-Lymphocytes; Vidarabine Phosphate	1996
Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Vidarabine Phosphate	1990
Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:3 Topics: Adult; Aged; Arabinonucleotides; Bone Marrow; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Vidarabine Phosphate	1985
Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas. American journal of clinical oncology, 1987, Volume: 10, Issue:4 Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Vidarabine Phosphate	1987